- Around 72,000 people have volunteered to participate in future vaccine studies following the launch of the NHS Covid-19 vaccine research
- Around 60 million doses of the Covid-19 vaccine would be provided by them to the UK
- The human clinical studies of the vaccine are said to begin in September followed by a Phase 3 study in December 2020.
London: Today, the UK Government made an announcement regarding the early access to the Covid-19 vaccine. With today’s announcement, the government has now secured early access to four different types of immunization and a total of 250 million doses, giving the UK the most likely chance of finding a safe and effective vaccine at the quickest speed.
The pharmaceutical company GSK and Sanofi Pasteur combined have proven to be the largest manufacturer of vaccines in the world. Around 60 million doses of the Covid-19 vaccine would be provided by them to the UK. If the vaccine shows a positive result then it is estimated that by 2021, the UK would be able to vaccinate the priority groups such as frontline health and social care workers.
The President of GSK Vaccines, Roger Connor said that they believe the adjuvanted vaccine candidate has the potential to play a significant role in overcoming the COVID-19 pandemic, both in the UK and around the world. Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur commented that they are pleased to cooperate with the UK Government as well as various other countries as a part of their ongoing efforts to ensure a safe and effective vaccine.
However, the human clinical studies of the vaccine are said to begin in September followed by a Phase 3 study in December 2020. The announcement was another encouraging development for the UK added Iain Stewart the UK Government Minister for Scotland. He further added that the growing portfolio of vaccines was a result of the UK Government’s work to keep people across the country safe and provide long-term protection from Covid-19.
Around 72,000 people have volunteered to participate in future vaccine studies following the launch of the NHS Covid-19 vaccine research. The goal is to get 5,00,000 people signed up by October for which the Government has requested, the citizens of the country to be a volunteer for clinical studies.
The Chair of the UK Government’s Vaccines Taskforce, Kate Bingham said that the agreement between the two pharma companies can add another type of vaccine to the three types of vaccine which they have already secured. The diversity of the vaccine types is significant as they do not know which type will prove to generate a safe response to the deadly virus. Moreover, she added the fact that the vaccine might not prevent getting the virus but reduces symptoms.
Alok Sharma the Business Secretary said that the scientists and researchers of the UK are working swiftly to invent a safe and effective vaccine at a scale never seen before though there is no guarantee. Meanwhile, it is important to secure early access to a diverse range of vaccine candidates like GSK and Sanofi to increase the chances of finding one that works so it can protect the public said the Minister.